Search - tctmd.com

Displaying 421 - 440 of 4015

Sort: Relevancy | Date

News Daily News

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

Todd Neale

November 21, 2022

News Daily News

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Yael L. Maxwell

November 21, 2022

News Daily News

Many STEMI Patients Not Treated Within National Time Goals

Michael O'Riordan

November 15, 2022

News Conference News AHA 2022

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Yael L. Maxwell

November 10, 2022

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

L.A. McKeown

November 07, 2022

News Conference News AHA 2022

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

Shelley Wood

November 06, 2022

News Conference News AHA 2022

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Michael O'Riordan

November 04, 2022

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

Presentation Cardiovascular Interventions 2022

OCT GUIDED DES DAPT & LIPID MANGEMENT

Presenter: Richard Shlofmitz

October 28, 2022

News Daily News

New Biomarker-Based Risk Score Performs Well in ACS

Michael O'Riordan

October 25, 2022

News Conference News TCT 2022

Late Catch-up Sours SUGAR for Polymer-Free Stent in Diabetic Patients

Yael L. Maxwell

September 27, 2022

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

Presentation TCT 2022

Two-Year Outcomes of the Randomized Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) Trial

Presenter: Pablo Salinas

September 19, 2022

Presentation TCT 2022

Cutting Balloon to Optimize Predilatation for Stent Implantation: The COPS Randomized Trial

Presenter: Antonio Mangieri

September 19, 2022

Presentation TCT 2022

DynamX Bioadaptor and Desyne BDS+

Presenter: Alexandre Cunha Abizaid

September 19, 2022

Presentation TCT 2022

IoNir Hybrid Coronary DES System

Presenter: Haim Danenberg

September 19, 2022

Presentation TCT 2022

Safety and Performance of a Sirolimus Eluting Resorbable Coronary Magnesium Scaffold (DREAMS 3G): The BIOMAG-1 FIH Trial

Presenter: Michael Haude

September 19, 2022

Presentation TCT 2022

Drug Elution: Challenges and Opportunities

Presenter: Sahil Parikh

September 18, 2022

Presentation TCT 2022

Coronary DCB in HBR Patients: An Alternative to DES?

Presenter: Tuomas Rissanen

September 18, 2022

Presentation TCT 2022

Role of Drug-Eluting Technologies as Definitive Therapy

Presenter: Beau Hawkins

September 18, 2022

Advertisement

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Many STEMI Patients Not Treated Within National Time Goals

Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

OCT GUIDED DES DAPT & LIPID MANGEMENT

New Biomarker-Based Risk Score Performs Well in ACS

Late Catch-up Sours SUGAR for Polymer-Free Stent in Diabetic Patients

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Two-Year Outcomes of the Randomized Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) Trial

Cutting Balloon to Optimize Predilatation for Stent Implantation: The COPS Randomized Trial

DynamX Bioadaptor and Desyne BDS+

IoNir Hybrid Coronary DES System

Safety and Performance of a Sirolimus Eluting Resorbable Coronary Magnesium Scaffold (DREAMS 3G): The BIOMAG-1 FIH Trial

Drug Elution: Challenges and Opportunities

Coronary DCB in HBR Patients: An Alternative to DES?

Role of Drug-Eluting Technologies as Definitive Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content